Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.275
Bid: 4.15
Ask: 4.40
Change: -0.025 (-0.58%)
Spread: 0.25 (6.024%)
Open: 4.30
High: 4.325
Low: 4.275
Prev. Close: 4.30
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Awards under Long-Term Incentive Plan

31 Aug 2023 18:25

RNS Number : 0270L
Eden Research plc
31 August 2023
 

31 August 2023

 

Eden Research plc

 

("Eden" or "the Company")

 

Grant of Awards under Long-Term Incentive Plan

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, confirms the grant of options under the Company's Long Term Incentive Plan ("LTIP") to Sean Smith, Chief Executive Officer, and Alex Abrey, Chief Finance Officer (together the "Executives"), as follows:

 

The Company has made a grant to the Executives, in respect of 2022 in order to ensure continuity of long term incentive, of options over 8,698,909 new Ordinary Shares in Eden ("the Options"), at a strike price of 5.05p each, being the 2022 Volume Weighted Average Price, in the amounts of 4,968,000 awarded to Sean Smith and 3,730,909 awarded to Alex Abrey.

 

The Options expire on 31 August 2027 and vest as follows:

 

1/3 upon grant

1/3 12 months from the date of grant

1/3 24 months from the date of grant

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail.

 

Separately, the Board has agreed that it will extend the exercise date to 31 December 2023 for the 3,500,000 options (2,000,000 awarded to Sean Smith and 1,500,000 awarded to Alex Abrey) with a strike price of 6p which were granted to the Executives in April 2021 under the Company's LTIP and which were due to expire on 30 June 2023.

 

The extension has been agreed to due to the unusually long closed period that the Executives were placed in prior to the options' expiration date.

 

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean SmithAlex Abrey

 

01285 359 555

Cenkos Securities plc (Nominated advisor and broker)

 

Giles Balleny / Max Gould (corporate finance)Michael Johnson (sales)

 

020 7397 8900

Hawthorn Advisors (Financial PR)

 

Simon Woods

Felix Meston

eden@hawthornadvisors.com

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Sean Smith

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Eden Research plc

b)

 

LEI

 

213800ZWTYTVQQSM3J85

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Options over ordinary shares of 1 pence each

 

 

GB0001646941

b)

 

Nature of the transaction

 

Grant of options

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

5.05p

4,968,000

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

 

N/A

e)

 

Date of the transaction

 

31 August 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Alex Abrey

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Eden Research plc

b)

 

LEI

 

213800ZWTYTVQQSM3J85

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Options over ordinary shares of 1 pence each

 

 

GB0001646941

b)

 

Nature of the transaction

 

Grant of options

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

5.05p

3,730,909

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

 

N/A

e)

 

Date of the transaction

 

31 August 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSDDFWFEDSEEA
Date   Source Headline
1st Sep 20157:03 amRNSProduct approval in Greece
24th Aug 20157:00 amRNSTerpeneTech Licence Agreement and Investment
25th Jun 20157:00 amRNSActive substances approved for MRL exemption
10th Jun 201512:25 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
27th May 20157:00 amRNSDirector/PDMR Shareholding
26th May 20157:01 amRNSEU Product Authorisation
20th May 201510:07 amRNSPosting of Annual Report & Notice of AGM
20th May 20157:00 amRNSAgreement with Sipcam covering new products
11th May 20157:00 amRNSAppointment of a Director and Share Options
13th Apr 20157:00 amRNSOption agreement with Taminco
30th Mar 20157:00 amRNSFinal Results
18th Feb 201511:08 amRNSDeath of a Director
2nd Feb 20157:00 amRNSGrant of Patent in South Korea
8th Jan 20157:00 amRNSDirectorate Change
19th Dec 20147:00 amRNSProgress on EU zone approval
1st Dec 20147:00 amRNSLicence Agreement with SUMIAGRO
28th Nov 20147:00 amRNSConversion of all outstanding debt
21st Nov 20143:26 pmRNSPlacing to raise £750,000
21st Nov 20147:00 amRNSLicence Agreement with SIPCAM
29th Sep 20147:00 amRNSSuccessful trials in Greece to combat Botrytis
29th Sep 20147:00 amRNSHalf Yearly Report
18th Aug 20147:00 amRNSDirectorate changes & share options
11th Aug 20147:00 amRNSEvaluation agreement for nematicide
1st Jul 20147:00 amRNSNotice of Decision of Patent in South Korea
26th Jun 201412:37 pmRNSAGM Statement
6th Jun 201410:46 amRNSPosting of Annual Report & Notice of AGM
6th Jun 20147:00 amRNSExtension of TerpeneTech licence agreement
30th May 20147:00 amRNSPreliminary Results
15th May 20147:00 amRNSNotice of Allowance for Mexican patent
8th May 20145:12 pmRNSDeath of a Director
24th Apr 20147:00 amRNSNotice of Allowance for Canada patent
22nd Apr 20147:01 amRNSFirst commercial products launched with Eden tech
10th Mar 20147:00 amRNSFurther progress in EU product approval
13th Jan 20147:00 amRNSData Access Licence and Royalty Agreement
19th Nov 201312:54 pmRNSHolding(s) in Company
18th Nov 201311:48 amRNSHolding(s) in Company
9th Oct 20137:00 amRNSNotice of Allowance from ARIPO
24th Sep 20137:00 amRNSHalf Yearly Report
28th Aug 20137:00 amRNSNotice of Allowance
27th Aug 201310:33 amRNSHolding(s) in Company
24th Jun 20131:39 pmRNSResult of AGM
24th Jun 20137:00 amRNSAGM Statement
5th Jun 20137:00 amRNSLicence agreement for head lice treatment
31st May 20135:22 pmRNSPosting of Annual Report & Notice of AGM
31st May 20137:08 amRNSPreliminary Results
20th May 20137:00 amRNSEU approval for active substances
25th Apr 20137:00 amRNSNotice of Allowance from ARIPO
16th Apr 201311:40 amRNSHolding(s) in Company
15th Mar 20137:00 amRNSMaster Encapsulation Patent Granted in Europe

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.